BioCryst Pharmaceuticals, Inc. (BCRX)
USD 7.31
(-2.4%)
USD 7.31
(-2.4%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 331.41 Million | 270.82 Million | 157.17 Million | 17.81 Million | 48.83 Million | 20.65 Million |
| Cost of Revenue | 4.66 Million | 6.59 Million | 7.26 Million | 1.67 Million | 4.1 Million | 471 Thousand |
| Gross Profit | 326.75 Million | 264.23 Million | 149.9 Million | 16.13 Million | 44.73 Million | 20.18 Million |
| Operating Expenses | 430.64 Million | 412.66 Million | 327.62 Million | 190.89 Million | 144.18 Million | 114.4 Million |
| Selling, General and Administrative Expenses | 213.89 Million | 159.37 Million | 118.81 Million | 67.92 Million | 37.12 Million | 29.51 Million |
| Research and Development Expenses | 216.56 Million | 253.29 Million | 208.8 Million | 122.96 Million | 107.06 Million | 84.88 Million |
| Other Expenses | - | 253.26 Million | 202.92 Million | 111.96 Million | 82.44 Million | 70.8 Million |
| Cost and Expenses | 435.12 Million | 419.26 Million | 334.89 Million | 192.56 Million | 148.29 Million | 114.87 Million |
| Operating Income | -103.7 Million | -148.43 Million | -177.72 Million | -174.75 Million | -99.45 Million | -94.22 Million |
| Interest Expense | 108.23 Million | 99.09 Million | 59.29 Million | 14.5 Million | 11.89 Million | 9.17 Million |
| Income Tax Expense | 310 Thousand | 2.73 Million | 2.25 Million | 13.75 Million | 11.16 Million | 2.14 Million |
| Earnings before Tax | -226.22 Million | -244.38 Million | -181.8 Million | -182.81 Million | -108.89 Million | -101.25 Million |
| Net Income | -226.53 Million | -247.11 Million | -184.06 Million | -196.56 Million | -120.06 Million | -101.25 Million |
| Earnings Per Share Basic | -1.18 | -1.33 | -1.03 | -1.18 | -1.04 | -0.98 |
| Earnings Per Share Diluted | -1.18 | -1.33 | -1.03 | -1.18 | -1.04 | -0.98 |
| Weighted Average Shares Outstanding | 192.19 Million | 185.9 Million | 179.11 Million | 167.26 Million | 115.6 Million | 103.18 Million |
| Weighted Average Shares Outstanding (Diluted) | 192.19 Million | 185.9 Million | 179.11 Million | 167.26 Million | 115.6 Million | 103.18 Million |
| Gross Margin | 0.99 | 0.98 | 0.95 | 0.91 | 0.92 | 0.98 |
| EBIT Margin | -0.35 | -0.53 | -1.13 | -9.28 | -2.00 | -4.45 |
| Profit Margin | -0.68 | -0.91 | -1.17 | -11.04 | -2.46 | -4.90 |
| EBITDA | -116.33 Million | -143.85 Million | -121.73 Million | -167.56 Million | -96.28 Million | -90.36 Million |
| Earnings Before Tax Margin | -0.31 | -0.55 | -1.13 | -9.81 | -2.04 | -4.56 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 117.08 Million | 109.33 Million | 92.76 Million | 93.4 Million | 331.41 Million | 86.74 Million |
| Cost of Revenue | 3.22 Million | 2.05 Million | 1.26 Million | 2.06 Million | 6.31 Million | 1.13 Million |
| Gross Profit | 113.85 Million | 107.27 Million | 91.49 Million | 91.34 Million | 325.09 Million | 85.6 Million |
| Operating Expenses | 106.16 Million | 98.51 Million | 105.85 Million | 134.01 Million | 428.8 Million | 97.52 Million |
| Selling, General and Administrative Expenses | 65.08 Million | 61.21 Million | 59.36 Million | 64.38 Million | - | 50.64 Million |
| Research and Development Expenses | 41.08 Million | 37.3 Million | 46.49 Million | 69.62 Million | - | 46.87 Million |
| Other Expenses | 17 Thousand | 35 Thousand | 127 Thousand | 180 Thousand | 180 Thousand | 37 Thousand |
| Cost and Expenses | 109.39 Million | 100.57 Million | 107.12 Million | 136.07 Million | 435.12 Million | 98.66 Million |
| Operating Income | 7.69 Million | 8.76 Million | -14.36 Million | -42.67 Million | -103.7 Million | -11.92 Million |
| Interest Expense | 24.82 Million | 24.73 Million | 24.5 Million | 24.58 Million | 108.23 Million | 27.34 Million |
| Income Tax Expense | 586 Thousand | 172 Thousand | 365 Thousand | -1.43 Million | 310 Thousand | 330 Thousand |
| Earnings before Tax | -13.44 Million | -12.5 Million | -35.01 Million | -63.16 Million | -226.22 Million | -35.81 Million |
| Net Income | -14.03 Million | -12.67 Million | -35.37 Million | -61.73 Million | -226.53 Million | -36.14 Million |
| Earnings Per Share Basic | -0.07 | -0.06 | -0.17 | -0.31 | - | -0.19 |
| Earnings Per Share Diluted | -0.07 | -0.06 | -0.17 | -0.31 | - | -0.19 |
| Weighted Average Shares Outstanding | 206.9 Million | 206.42 Million | 206.06 Million | 201.4 Million | 192.19 Million | 189.64 Million |
| Weighted Average Shares Outstanding (Diluted) | 206.9 Million | 206.42 Million | 206.06 Million | 201.4 Million | 192.19 Million | 189.64 Million |
| Gross Margin | 0.97 | 0.98 | 0.99 | 0.98 | 0.98 | 0.99 |
| EBIT Margin | 0.10 | 0.08 | -0.11 | -0.45 | - | -0.09 |
| Profit Margin | -0.12 | -0.12 | -0.38 | -0.66 | -0.68 | -0.42 |
| EBITDA | 11.38 Million | 9.08 Million | -10.15 Million | -42.24 Million | - | -7.73 Million |
| Earnings Before Tax Margin | 0.07 | 0.08 | -0.15 | -0.46 | -0.31 | -0.14 |
RWWI
AVROIND
JUBLINGREA
EEGUF
MTO
INPST